leadf
logo-loader
viewMindset Pharma Inc
(
CSE:MSETOTCQB:MSSTFFRA:9DF
)

Mindset Pharma selects Treatment-Resistant Depression and End of Life Cancer Angst as initial target indications for MSP-1014

MSP-1014 is a novel patent-pending drug candidate that shows potential to be a safer second-generation psilocybin-like therapy with a decreased potential for side effects

Mindset Pharma Inc - Mindset Pharma Inc. selects Treatment-Resistant Depression and End of Life Cancer Angst as initial target indications for lead clinical candidate MSP-1014
In a head-to-head comparison with psilocybin, MSP-1014 demonstrated superior head twitch response and minimal change in core body temperature, which suggests the compound potentially produces a greater hallucinogenic response with an improved safety profile

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF). has selected Treatment-Resistant Depression (TRD) and End of Life Cancer Angst as initial target indications for its lead clinical candidate MSP-1014.

The company said MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second-generation psilocybin-like therapy with decreased potential for side effects.

“Psilocybin has demonstrated encouraging efficacy in treating TRD and End of Life Cancer Angst in a number of clinical studies and we believe our novel drug candidate, MSP-1014, represents a safer and more scalable evolution to its psilocybin predecessor,” said James Lanthier, CEO of Mindset, in a statement. 

READ: Mindset Pharma reports encouraging safety data concerning its Family 4 group of DMT analogs

“TRD represents a large and untreated population with a third of major depressive disorder sufferers resistant to presently available treatments, while End of Life Angst is a major cause of depression and anxiety with limited treatment options. We see an opportunity to bridge a significant treatment gap with our next generation medicine and plan to advance MSP-1014, as well as other candidates across our library of patent-pending compounds, through the regulatory process as quickly as possible,” Lanthier added.

Joseph Araujo, chief scientific officer of Mindset, noted that in a head-to-head comparison with psilocybin, MSP-1014 demonstrated superior head twitch response and minimal change in core body temperature, which suggests its compound potentially produces a greater hallucinogenic response with an improved safety profile.

“Furthermore, MSP-1014 leverages Mindset’s proprietary psilocybin synthesis process, enabling scale-up efficiency in manufacturing and positioning us well for progressing our novel drug candidate through to clinical trials,” he said.

Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Mindset Pharma Inc

Follow
CSE:MSET

Price: 0.74 CAD

Market Cap: $53.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mindset Pharma say latest results further validate lead candidate's...

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay. Araujo and Lanthier...

1 week, 5 days ago

2 min read